Eli Lilly has introduced Mounjaro (tirzepatide) in India, a groundbreaking drug for Type 2 diabetes & obesity.
Key Highlights
- Approved by the Central Drugs Standard Control Organization (CDSCO), Mounjaro is now available in single-dose vials, with pricing set at Rs 3,500 for a 2.5 mg vial and Rs 4,375 for a 5 mg vial.
- Eli Lilly claims that Mounjaro is the first medication to target both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, offering a novel approach to metabolic health management.
Clinical Trial Results
- SURMOUNT-1: Adults taking the highest dose of Mounjaro (15 mg) lost an average of 21.8 kg, while those on the lowest dose (5 mg) lost 15.4 kg, compared to 3.2 kg in the placebo group.
- SURPASS (Diabetes Study): It examined Mounjaro’s efficacy in patients with Type 2 diabetes. The drug reduced A1C levels by up to 2.4%, whether used alone or in combination with commonly prescribed diabetes medications.
(Source: DD News)
